Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
FASEB J. 2020 Jul;34(7):9372-9392. doi: 10.1096/fj.202000173R. Epub 2020 May 28.
Mutations in the human cystathionine beta synthase (CBS) gene are known to cause endothelial dysfunction responsible for cardiovascular and neurovascular diseases. CBS is the predominant hydrogen sulfide (H S)-producing enzyme in endothelial cells (ECs). Recently, H S was shown to attenuate ROS and improve mitochondrial function. Mitochondria are metabolic organelles that actively transform their ultrastructure to mediate their function. Therefore, we questioned whether perturbation of CBS/H S activity could drive mitochondrial dysfunction via mitochondrial dynamics in ECs. Here we demonstrate that silencing CBS induces mitochondria fragmentation, attenuates efficient oxidative phosphorylation, and decreases EC function. Mechanistically, CBS silencing significantly elevates ROS production, thereby leading to reduced mitofusin 2 (MFN2) expression, decouple endoplasmic reticulum-mitochondria contacts, increased mitochondria fission, enhanced receptor-mediated mitophagy, and increased EC death. These defects were significantly rescued by the treatment of H S donors. Taken together our data highlights a novel signaling axis that mechanistically links CBS with mitochondrial function and ER-mitochondrial tethering and could be considered as a new therapeutic approach for the intervention of EC dysfunction-related pathologies.
已知人类胱硫醚β合酶(CBS)基因的突变会导致内皮功能障碍,从而引发心血管和神经血管疾病。CBS 是内皮细胞(ECs)中主要的硫化氢(H₂S)产生酶。最近,H₂S 被证明可以减轻 ROS 并改善线粒体功能。线粒体是代谢细胞器,它们会主动改变超微结构以调节其功能。因此,我们质疑 CBS/H₂S 活性的干扰是否会通过 ECs 中的线粒体动力学导致线粒体功能障碍。在这里,我们证明了沉默 CBS 会诱导线粒体碎片化,减弱有效的氧化磷酸化,并降低 EC 功能。在机制上,CBS 沉默会显著增加 ROS 的产生,从而导致融合蛋白 2(MFN2)表达减少、内质网-线粒体接触解偶联、线粒体分裂增加、受体介导的线粒体自噬增强以及 EC 死亡增加。这些缺陷可以通过 H₂S 供体的治疗得到显著挽救。综上所述,我们的数据强调了一个新的信号轴,该信号轴从机制上把 CBS 与线粒体功能和内质网-线粒体连接联系起来,并可以被视为干预与 EC 功能障碍相关的病理学的一种新的治疗方法。